论文信息 - Neurological Events Reported after COVID‐19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System - 字舞流文

Neurological Events Reported after COVID‐19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System

To identify the rates of neurological events following administration of mRNA (Pfizer, Moderna) or adenovirus vector (Janssen) vaccines in the U.S.

J. Sejvar | E. Beghi | T. Wijeratne | A. Winkler | A. Guekht | Nina Singh | A. Shalash | D. García‐Azorín | Jessica Hunter | R. Allegri | Michele Santacatterina | P. Satishchandra | A. Tamborska | M. Netravathi | F. Hoo | B. Baykan | K. Thakur | D. Zhuravlev | M. Spatola | J. Frontera | G. Delgado-García | M. F. Doheim | Abdul Hanif Khan Yusof Khan | I. Calandri | S. Lant | Lindsay Tetreault | A. Safwat | E. Warburton | S. Faissner | Tamara M. Welte | M. Zinchuk | Haşim Gezegen | E. Westenberg | Lana Blinc | A. Boruah | Maja Bresjanac | Yuliya Bryzgalova | Rashmi Devaraj | Jeyanthan Charles James | Nana Yaa Kyei‐Frimpong | Nicholas Mulchan | Svetlana Pikovskaya | Nihara Abdul Rasheed | Vivian Ssonko | J. Weng | D. Xia | Abhilasha P. Boruah | N. Singh | G. Vidali | T. Welte | Jessica L Hunter | Doris Xia | A. H. K. Yusof Khan

[1] K. Khunti,et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection , 2021, Nature Medicine.

[2] E. Woo,et al. Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome, February-July 2021. , 2021, JAMA.

[3] E. Woo,et al. Use of COVID-19 Vaccines After Reports of Adverse Events Among Adult Recipients of Janssen (Johnson & Johnson) and mRNA COVID-19 Vaccines (Pfizer-BioNTech and Moderna): Update from the Advisory Committee on Immunization Practices — United States, July 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[4] R. Thomas,et al. Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder , 2021, Journal of Neurology, Neurosurgery, and Psychiatry.

[5] N. Fowler,et al. Incidence of Bell Palsy in Patients With COVID-19. , 2021, JAMA otolaryngology-- head & neck surgery.

[6] H. Mangat,et al. Guillain‐Barré Syndrome following ChAdOx1‐S/nCoV‐19 Vaccine , 2021, Annals of neurology.

[7] S. Anderson,et al. U.S. Population-Based background incidence rates of medical conditions for use in safety assessment of COVID-19 vaccines , 2021, Vaccine.

[8] J. Geddes,et al. Cerebral venous thrombosis and portal vein thrombosis: A retrospective cohort study of 537,913 COVID-19 cases , 2021, EClinicalMedicine.

[9] E. Moro,et al. Global Incidence of Neurological Manifestations Among Patients Hospitalized With COVID-19—A Report for the GCS-NeuroCOVID Consortium and the ENERGY Consortium , 2021, JAMA network open.

[10] J. Gargano,et al. Updated Recommendations from the Advisory Committee on Immunization Practices for Use of the Janssen (Johnson & Johnson) COVID-19 Vaccine After Reports of Thrombosis with Thrombocytopenia Syndrome Among Vaccine Recipients — United States, April 2021 , 2021, MMWR. Morbidity and mortality weekly report.

[11] G. Román,et al. Acute Transverse Myelitis (ATM):Clinical Review of 43 Patients With COVID-19-Associated ATM and 3 Post-Vaccination ATM Serious Adverse Events With the ChAdOx1 nCoV-19 Vaccine (AZD1222) , 2021, Frontiers in Immunology.

[12] M. Suchard,et al. Characterizing the incidence of adverse events of special interest for COVID-19 vaccines across eight countries: a multinational network cohort study , 2021, medRxiv.

[13] J. Anesi. The advisory Committee on Immunization practices’ updated interim recommendation for allocation of COVID-19 vaccine—United states, December 2020 , 2021, American Journal of Transplantation.

[14] B. Bell,et al. The Advisory Committee on Immunization Practices’ Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020 , 2021, MMWR. Morbidity and mortality weekly report.

[15] K. Melmed,et al. A Prospective Study of Neurologic Disorders in Hospitalized Patients With COVID-19 in New York City , 2020, Neurology.

[16] Y. Tie,et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020 , 2020, MMWR. Morbidity and mortality weekly report.

[17] B. Boeve,et al. Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis , 2018, Annals of neurology.

[18] Matthew Wise,et al. Population Incidence of Guillain-Barré Syndrome: A Systematic Review and Meta-Analysis , 2011, Neuroepidemiology.

[19] J. Sejvar,et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. , 2011, Vaccine.

[20] J. Raphaël,et al. [Guillain-Barré syndrome]. , 2005, La Revue du praticien.

[21] M. Salive,et al. An overview of the vaccine adverse event reporting system (VAERS) as a surveillance system. VAERS Working Group. , 1999, Vaccine.

[22] S. Cochi,et al. The Vaccine Adverse Event Reporting System (VAERS). , 1994, Vaccine.

[23] R. Mandler,et al. Transverse Myelitis: Retrospective Analysis of 33 Cases, With Differentiation of Cases Associated With Multiple Sclerosis and Parainfectious Events , 1993 .

[24] J. Fleiss,et al. Statistical methods for rates and proportions , 1973 .

[25] P. Mahadevan,et al. An overview , 2007, Journal of Biosciences.

[26] F. Varricchio,et al. The vaccine adverse event reporting system. , 1998, Journal of toxicology. Clinical toxicology.